Wegovy tabletter: the oral semaglutide tablet explained for UK readers

The misconception: Wegovy tablets are just Rybelsus with a different label

This is the question our prescribers hear most often about the tablet, and it is worth clearing up straight away. Rybelsus does contain oral semaglutide, but it is licensed for type 2 diabetes at doses of 3 mg, 7 mg and 14 mg. The Wegovy weight-loss tablet is an entirely separate licensed product, approved for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or raised cholesterol. The dosing ladder is completely different: 1.5 mg, then 4 mg, then 9 mg, then 25 mg at maintenance. Those 3 mg, 7 mg and 14 mg Rybelsus strengths have no place in the Wegovy weight-loss schedule and should never be confused with it.

The MHRA's approval on 11 June 2026 was specifically for the weight-management indication, and the UK was the first in Europe to grant it. If you come across a provider describing a 3 mg or 7 mg tablet as a step in a weight-loss programme, that is inaccurate. A prescriber working from the correct Wegovy information will follow the 1.5 mg starting dose and work upward from there.

What the trial evidence actually showed

The phase-3 OASIS 4 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, and followed them for 64 weeks. Average weight loss across all participants was around 13.6%, compared with roughly 2.4% in the placebo group, when measured regardless of how consistently people took the tablet. Among those who stayed fully adherent to the regimen throughout, average loss reached approximately 16.6%. That second figure, cited by Novo Nordisk in the UK approval announcement, is the one worth framing carefully: it reflects the best-case group rather than the typical participant. For most readers, the 13.6% figure is the more honest reference point.

The most frequently reported side effects in the trial were gastrointestinal (nausea, diarrhoea, vomiting and constipation) affecting around 74% of participants on the tablet versus 42% on placebo. These effects were generally mild to moderate and tended to settle as the body adjusted. Guidance on managing side effects while on Wegovy applies broadly to the tablet form too, since the active ingredient is the same.

How the tablet is taken, and why the instructions are specific

Oral semaglutide has very particular absorption requirements. The tablet needs to be taken first thing in the morning, on a completely empty stomach, with a small amount of plain water, no more than about 120 ml, roughly half a standard glass. After swallowing it, you wait at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines. Skip that window and absorption drops sharply. Think of it like the tablet before the kettle goes on, it has to come first, every day, without exception.

The practical upside is that unlike the Wegovy injection, no refrigeration is required. The tablets store at room temperature, which removes the logistical challenge of travelling with a cold chain. The timing of semaglutide doses matters more for the tablet than for almost any other oral medicine, so this is not a detail to overlook. The full instructions, including what to do if a dose is missed, are set out in the Patient Information Leaflet and should be followed exactly as written there, not guessed at.

Who can access Wegovy tablets in the UK right now

The licensed eligibility criteria mirror those for the injection: adults with a BMI of 30 or above, or 27 to 29.9 alongside a qualifying weight-related condition. Lower BMI thresholds may apply for some ethnic backgrounds under UK clinical guidance. Because no NICE technology appraisal has yet been completed for the tablet formulation, it is not currently available through the NHS, and a private prescription is the only route. That means a clinical assessment with a prescriber who can review your full medical history and confirm the treatment is appropriate for you personally.

For people already established on the 2.4 mg weekly injection, switching to the 25 mg tablet may be possible subject to prescriber assessment, and our guidance on how to make semaglutide work better is worth reading alongside that conversation, as the same principles apply whether you are on the tablet or the injection. If you are curious about how the tablet and the injection compare in practice, the evidence comparing Wegovy's different formulations is worth reading before your consultation. The MHRA's approval announcement provides the regulatory detail behind the UK licence. Wegovy tablets, like the injection, carry a Black Triangle designation, meaning the MHRA collects enhanced safety information while the medicine builds its post-marketing record, as noted on the NHS semaglutide medicines page.

If you would like to find out whether oral semaglutide might be right for you, check your eligibility with our prescribers, consultation is free, and every application is personally reviewed the same day.